| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-850 | |
| Phytochemical name or plant extracts | Minecoside | |
| PMID | 32016931 | |
| Literature evidence | Overall, our results suggest that minecoside can be a novel anticancer agent that can inhibit cancer metastasis through inhibition of CXC chemokine receptor 4 expression. | |
| IUPAC name | [(1S,2S,4S,5S,6R,10S)-2-(hydroxymethyl)-10-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,9-dioxatricyclo[4.4.0.02,4]dec-7-en-5-yl] (E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoate | |
| Phytochemicals’ class or type of plant extracts | Hydroxycinnamic acid | |
| Source of phytochemicals or plant Extracts | Veronica peregrina | |
| Geographical availability | Alabama, Alberta, Argentina Northeast, Argentina Northwest, Argentina South, Arizona, Arkansas, Bahamas, Bolivia, Brazil South, Brazil Southeast, British Columbia, California, Chile Central, Chile South, Colombia, Colorado, Connecticut, Costa Rica, Delaware, District of Columbia, Dominican Republic, Ecuador, Florida, Georgia, Guatemala, Honduras, Idaho, Illinois, Indiana, Iowa, Jamaica, Kansas, Kentucky, Louisiana, Maine, Manitoba, Maryland, Massachusetts, Mexico Central, Mexico Gulf, Mexico Northeast, Mexico Northwest, Mexico Southeast, Mexico Southwest, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Brunswick, New Hampshire, New Jersey, New Mexico, New York, Newfoundland, North Carolina, North Dakota, Northwest Territorie, Nova Scotia, Ohio, Oklahoma, Ontario, Oregon, Panamá, Pennsylvania, Peru, Prince Edward I., Puerto Rico, Québec, Rhode I., Saskatchewan, South Carolina, South Dakota, Tennessee, Texas, Uruguay, Utah, Venezuela, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, Yukon | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Colon Cancer | |
| Target gene or protein | CXCR4 | |
| Gene or Protein evidence | In this study, we found that minecoside downregulates constitutive CXC chemokine receptor 4 expression in MDA-MB-231 breast cancer cells. | |
| Target pathways | STAT3 signaling pathway | |
| IC50 | NA | |
| Potency | Minecoside-mediated suppression of CXC chemokine receptor 4 expression inhibited CXC ligand 12-induced invasion of breast and colorectal cancer cells. Overall, our results suggest that minecoside can be a novel anticancer agent that can inhibit cancer metastasis through inhibition of CXC chemokine receptor 4 expression. | |
| Cell line/ mice model | MDA‑MB‑231, PANC1, SW480, HCT116, A2780, U266, A549, MCF-7 | |
| Additional information | Subsequently, MIN promoted the caspase-dependent apoptosis in MDA-MB-231 cells. Overall, results of the present study provide evidence that MIN exerted anticancer activity via inhibition of the STAT3 signaling pathway. | |
| PubChem ID | 12002015 | |
| Additional PMIDs | 35154425 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:812460-1 | |
| Safety | NA |